您正在浏览的是:生命科学学院 >> 导师风采 >> 博士研究生导师 >> 许岳慷 教授

许岳慷,男,江苏南京人,墨尔本大学哲学博士,现任安徽师范大学教授、博士生导师。 安徽省“百人计划”入选专家。安徽省“特聘教授”。安徽师范大学免疫学科学术带头人。 近年来在《Nature Immunology》、《Immunity》、《Journal of Experimental Medicine》、《Journal of Immunology》、《Journal of Biological Chemistry》等国际主流学术杂志发表论文二十余篇。担任《International Journal of Immunology Research》主编及《American Journal of Clinical and Experimental Immunology》编委等职。主持美国及澳大利亚科研基金3项,参与澳大利亚国立卫生医学研究院项目基金2项。 目前全职回国工作,其国内实验室与澳大利亚WEHI医学研究所联系紧密并签有科研合作协议,已送一名研究生在澳合作研究。欢迎广大博士生及研究生加入我们的新团队。

 

邮箱:yuekang.xu@hotmail.com


一、主要学习、工作经历和学术兼职:
1、学习经历
  • 1980 - 1985:中国安徽医科大学, 医学专业,学士

  • 1985 - 1987:中国安徽师范大学, 英语专业,学士

  • 2000 - 2004:澳洲墨尔本大学,医学生物学专业,博士

2、工作经历
  • 1987 - 1991: 安徽医科大学,助教

  • 1991 - 1998: 安徽省遗传医学中心,助理研究员

  • 1998 - 1999: 澳洲Monash大学,访问学者

  • 2000 - 2004: 澳洲墨尔本大学,博士生

  • 2004 - 2007: 澳洲Peter Mac Cancer Centre,博士后

  • 2007 - 2008: 澳洲Walter & Eliza Hall研究所,研究官员

  • 2009 - 2011: 澳洲Walter & Eliza Hall研究所,高级研究官员

  • 2011 - 2014: 澳洲墨尔本大学Bio21医学研究所,研究员

  • 2014 - 至今: 安徽师范大学生命科学学院,教授

3、 学术兼职
  • 国际免疫研究杂志主编

  • 美国临床和试验免疫学杂志编委

  • 美国免疫学杂志客座编辑

  • 澳洲国立卫生和医学研究院项目研究基金会评审员

  • 澳亚免疫协会会员

  • 国际Faculty of 1000 会员

  • 安徽省细胞生物学学会常委理事

  • 安徽省免疫学学会理事

、主要研究方向:
  • 免疫细胞的信号传导:当外界病原微生物侵入机体时,免疫细胞首先做出反应。本实验室主要研究免疫细胞在受到炎性刺激后,胞内信号通路中哪些分子发生了变化,这些变化最终如何改变免疫细胞功能和行为,以及根据这些变化找到并合成该分子的类似物或拮抗剂以控制炎性信号的发展,从而达到临床治疗的目的。

  • 树突状细胞的发育:树突状细胞在免疫反应中起着支配和主导作用。不同的生长因子和生长环境控制产生不同的树突状细胞。本实验室主要研究在树突状细胞的发育过程中哪些因素通过什么方式控制产生了什么类型的树突状细胞,这些树突状细胞功能上有什么区别,能主导着什么样的免疫反应,以及我们能否利用这些因素在体外定向生产这种树突状细胞回输体内干预免疫反应。

  • 免疫生化:树突状细胞不仅调节免疫应答而且大量产生胱抑素C。胱抑素C是一种蛋白酶抑制剂,控制着组织基质内蛋白溶酶的活性。同时它也是一种纤维化蛋白,可在血管内形成纤维沉淀而破坏血管内壁。本实验室主要研究哪些因素可以调节胱抑素C的分泌,哪些因素会诱导胱抑素C纤维化的形成及分泌,以及这些因素是否可以被用于临床来治疗因蛋白溶酶活性过高、过低或胱抑素C纤维化而导致的疾病(如动脉粥样硬化和阿茲海默症等)。

三、 目前主持或参与研究的主要课题:
  • 安徽省对外科学技术合作项目,炎症条件下树突状细胞发育和功能的分子机制研究(1604b0602017),2016-2018,30万,主持.

  • 澳大利亚国立卫生医学研究委员会项目基金 “Regulation of Cardiovascular Disease-Associated Protease Inhibitor Cystatin C for Therapeutic Application”. 2011-2013. $ 481,299 澳元,主持.

  • 澳大利亚国立卫生医学研究委员会Peter Doherty基金“Improving Anti-Tumor Therapy by Genetically Modifying CD4+ T cells”. 2006-2010. $ 349,129澳元, 主持.

  • 美国Susan Komen基金“Genetic Modification of Multiple Immune System Cells for Breast Cancer Therapy”. 2004-2006. $ 457,500澳元, 主持.

  • 澳大利亚国立卫生医学研究委员会项目基金 “Towards Effective Immunotherapy of Cancer Using Genetically Enhanced Lymphocytes” 2004-2006。$ 457,500澳元, 参与.

  • 澳大利亚国立卫生医学研究委员会项目基金“The Role of the Lyn Tyrosin Kinase in Autoimmunity” 2003-2005. $ 465,000澳元, 参与.

四、 近年主要学术成就:
(一) 论文:
  1. X Li, Y Ding, M Zi, L Sun, W Zhang, S Chen, Y Xu*:CD19, from bench to bedside. Immunol Lett, 183:86-95, 2017. (*Corresponding author)

  2. Xu, Y*, Ding, Y., Li, X., and Wu, X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol 93(5): 442-51.2015. (*Corresponding author)

  3. Xu Y*, Lindemann P, Vega-Ramos J, Zhang JG, Villadangos JA. Developmental Regulation of Synthesis and Dimerization of the Amyloidogenic Protease inhibitor Cystatin C in the Hematopoietic System. J Biol Chem. 289(14):9730-40. 2014.  (*corresponding author) 

  4. Xu Y*, Fairfax K, Light A, Huntington ND, Tarlinton DM. CD19 Differentially Regulates BCR Signalling through the Recruitment of PI3K. Autoimmunity. 2014 Jun 23:1-8. [Epub ahead of print]. (*corresponding author)

  5. Xu W, Pan H, Xu Y*, and Ye D. Interferon Regulatory Factor 5 and Autoimmune Lupus. Expert Rev Mol Med. 10.1017/erm2013.7. 2013.  (*senior author)

  6. Li B, Ye Q, Xu W, Li J, Ye D and Xu Y*. GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity. 46:409. 2013.  (*corresponding/senior author)

  7. Hu M, Crawford SA, Henstridge DC, Ng IH, Boey EJ, Xu Y, Febbraio MA, Jans DA, Bogoyevitch MA. p32 Protein Levels are Integral to Mitochondrial and Endoplasmic Reticulum Morphology, Cell Metabolism and Survival. Biochem J. 453:381. 2013

  8. Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM and Xu Y*. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol. 42:2889.  2012. (Highlighted in “In this issue” section of EJI, and propagandized in “Global Medical Discovery Series”).  (*corresponding/senior author)

  9. Xu WD. Pan HF, Ye DQ, and Xu Y*. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11:918. 2012.  (*senior author)

  10. Xu Y, Huntington ND, Harder K, Nandurkar H, Hibbs ML and Tarlinton. Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase. Immunol Cell Biol. 90:903. 2012 (Awarded 2012 ICB publication award).

  11. Zhan Y, Xu Y, Lew AM. The regulation of the development and function of dendritic cell subsets by GM-CSF:More than a hematopoietic growth factor. Mol Immunol 52:30. 2012.

  12. Leng R, Pan H, Ye D and Xu Y*. Potential role of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Imunol 1:28 (2012).  (*corresponding/senior author)

  13. Xu Y*, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea  H, Dickins RA and Villadangos JA. Interleukin-10 Controls Cystatin C Synthesis and Blood Concentration in Response to Inflammation through Regulation of IRF-8 Expression.  J. Immunol. 186:3666 (2011). (*corresponding author)

  14. Zhan Y, Carrington EM, van Nieuwenhuijze A, Bedoui S, Seah S, Xu Y, Wang N, Mintern JD, Villadangos JA, Wicks IP, Lew AM. GM-CSF increases cross-presentation and CD103 expression by mouse CD8(+) spleen dendritic cells. Eur J Immunol. 41:2585. 2011.

  15. Zhan Y, Xu Y, Seah S, Brady JL, Carrington EM, Cheers C, Croker BA, Wu L, Villadangos JA, Lew AM. Resident and monocyte-derived dendritic cells become dominant IL-12 producer under different conditions and signaling pathways. J. Immunol. 185(4):2125-33 (2010).

  16. Westwood J, Mayura-Guru P, Murray W, Pegram H, Amos S, Van Puyenbroek S, Cameron R, Smyth M, Xu Y, Darcy P,  and Kershaw M. Anti-tumor activity of genetically redirected T cells against orthotopic kidney cancer in mice. Open Gene Therapy BSP-TOGTJ-2009-1 (2010).

  17. Zhan Y, Gerondakis S, Coghill E,  Bourges D,  Xu Y, Brady JL, Wicks I, and  Lew AM.  GITR expression  by T cells is reciprocally regulated by NF-kappa B and NFA.  J Immunol.  181(8):5405-13 (2008).

  18. Xu Y*, Zhan Y, Lew AM, Naik SH and Kershaw MH.   Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol  179(11):7577-84 (2007). (Listed by “Faculty of 1000” as “must read” article). (*corresponding author)

  19. Xu Y, Darcy PK, and Kershaw MH.  Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther. 14(9):773-80 (2007).

  20. Murphy A, Westwood JA, Brown LE, Teng MW, Moeller M, Xu Y, Smyth MJ, Hwu P, Darcy PK, Kershaw MH. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther.  14(5):499-508. (2007).

  21. Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, Strasser A, Tarlinton DM.  CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers.  Nat. Immunol. 7(2):190-8. (2006).

  22. Xu Y, Harder KW, Huntington ND, Hibbs ML, and Tarlinton DM.  Lyn tyrosine kinase:accentuating the positive and the negative. Immunity. 22:9-18 (2005).

  23. Huntington ND, Xu Y, Nutt S, Tarlinton DM.  A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary NK cells.  J. Exp. Med. 201:1421-33 (2005).

  24. Xu Y, Davies J, Ramsland P, Holmdahl R, Kumar N, Scealy M, Rowley M. Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage display:implications for autoimmunity and molecular mimicry. Mol. Immunol. 41:411-9 (2004).

  25. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A.   Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells.  J Exp. Med. 198:1119-26 (2003).

  26. Xu Y, Beavitt SJ, Harder KW, Hibbs ML, Tarlinton DM.  The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent.  J. Immunol .  169:6910-8 (2002).

(二)近年主要获奖及荣誉称号
  • 2014:安徽省“百人计划”入选专家 安徽省“特聘教授”。中国,安徽。

  • 2013:ICB Publications of the Year Runner Up Awards, Australia

  • 2011-2013:NHMRC Project Grant (APP1006428, CIA), Australia.

  • 2010:International Postdoctoral Travel Award from Australian Society of Immunology, Australia.

  • 2008:International Travel Bursary from 4th Congress of the Federation of Immunology Societies of Asia-Oceania (FIMSA), Taipei, Taiwan.

  • 2008:International Travel Award from Australian Society of Immunology.

  • 2006-2010:NHMRC Peter Doherty Fellowship, Australia.

  • 2006-2009:Susan Komen Postdoctoral Fellowship, Susan Komen Foundation, USA .

  • 2003:Student Award from Cold Spring Harbour Conference, New York, USA.

  • 2003:Edith Moffatt Travel Scholarship from Walter & Eliza Hall Institute of Medical Research, Australia.

  • 2000-2004:Melbourne International Fee Remission Scholarship (MIFRS), University of Melbourne, Australia.

  • 2000-2004:Melbourne International Research Scholarship (MIRS), University of Melbourne, Australia.

  • 1999 :Overseas Postgraduate Research Scholarship (OPRS), Victoria University, Australia.